Design, Synthesis, and Molecular Docking Studies of Curcumin Hybrid Conjugates as Potential Therapeutics for Breast Cancer

Curcumin (CUR) has received great attention over the past two decades due to its anticancer, anti-inflammatory, and antioxidant properties. Similarly, Dichloroacetate (DCA), an pyruvate dehydrogenase kinase 1 (PKD1) inhibitor, has gained huge attention as a potential anticancer drug. However, the cl...

Повний опис

Збережено в:
Бібліографічні деталі
Автори: Siva S. Panda (Автор), Queen L. Tran (Автор), Pragya Rajpurohit (Автор), Girinath G. Pillai (Автор), Sean J. Thomas (Автор), Allison E. Bridges (Автор), Jason E. Capito (Автор), Muthusamy Thangaraju (Автор), Bal L. Lokeshwar (Автор)
Формат: Книга
Опубліковано: MDPI AG, 2022-04-01T00:00:00Z.
Предмети:
Онлайн доступ:Connect to this object online.
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_80cceee1da974436be064b13a59d0cde
042 |a dc 
100 1 0 |a Siva S. Panda  |e author 
700 1 0 |a Queen L. Tran  |e author 
700 1 0 |a Pragya Rajpurohit  |e author 
700 1 0 |a Girinath G. Pillai  |e author 
700 1 0 |a Sean J. Thomas  |e author 
700 1 0 |a Allison E. Bridges  |e author 
700 1 0 |a Jason E. Capito  |e author 
700 1 0 |a Muthusamy Thangaraju  |e author 
700 1 0 |a Bal L. Lokeshwar  |e author 
245 0 0 |a Design, Synthesis, and Molecular Docking Studies of Curcumin Hybrid Conjugates as Potential Therapeutics for Breast Cancer 
260 |b MDPI AG,   |c 2022-04-01T00:00:00Z. 
500 |a 10.3390/ph15040451 
500 |a 1424-8247 
520 |a Curcumin (CUR) has received great attention over the past two decades due to its anticancer, anti-inflammatory, and antioxidant properties. Similarly, Dichloroacetate (DCA), an pyruvate dehydrogenase kinase 1 (PKD1) inhibitor, has gained huge attention as a potential anticancer drug. However, the clinical utility of these two agents is very limited because of the poor bioavailability and unsolicited side effects, respectively. We have synthesized fusion conjugates of CUR and DCA with an amino acids linker to overcome these limitations by utilizing the molecular hybridization approach. The molecular docking studies showed the potential targets of Curcumin-Modified Conjugates (CMCs) in breast cancer cells. We synthesized six hybrid conjugates named <b>CMC1-6</b>. These six CMC conjugates do not show any significant toxicity in a human normal immortalized mammary epithelial cell line (MCF10A) in vitro and C57BL/6 mice in vivo. However, treatment with <b>CMC1</b> and <b>CMC2</b> significantly reduced the growth and clonogenic survival by colony-formation assays in several human breast cancer cells (BC). Treatment by oral gavage of a transgenic mouse BC and metastatic BC tumor-bearing mice with <b>CMC2</b> significantly reduced tumor growth and metastasis. Overall, our study provides strong evidence that CUR and DCA conjugates have a significant anticancer properties at a sub-micromolar concentration and overcome the clinical limitation of using CUR and DCA as potential anticancer drugs. 
546 |a EN 
690 |a curcumin 
690 |a DCA 
690 |a amino acid 
690 |a molecular hybridization 
690 |a molecular docking 
690 |a breast cancer 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 15, Iss 4, p 451 (2022) 
787 0 |n https://www.mdpi.com/1424-8247/15/4/451 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/80cceee1da974436be064b13a59d0cde  |z Connect to this object online.